Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model
The axis of Programmed cell death-1 receptor (PD-1) with its ligand (PD-L1) plays a critical role in colorectal cancer (CRC) in escaping immune surveillance, and blocking this axis has been found to be effective in a subset of patients. Although blocking PD-L1 has been shown to be effective in 5–10%...
Main Authors: | Rinku Dutta, Roukiah Khalil, Karthick Mayilsamy, Ryan Green, Mark Howell, Srinivas Bharadwaj, Shyam S. Mohapatra, Subhra Mohapatra |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.706133/full |
Similar Items
-
SARS–CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges
by: Andrew R. McGill, et al.
Published: (2021-02-01) -
Role of Cannabidiol for Improvement of the Quality of Life in Cancer Patients: Potential and Challenges
by: Ryan Green, et al.
Published: (2022-10-01) -
Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
by: Roukiah Khalil, et al.
Published: (2023-06-01) -
Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs
by: Mark C. Howell, et al.
Published: (2021-11-01) -
Ultrafast-UV laser integrating cavity device for inactivation of SARS-CoV-2 and other viruses
by: Sharad Ambardar, et al.
Published: (2022-07-01)